Navigation Links
Intarcia Therapeutics Appoints Nancy Thornberry to Board of Directors
Date:12/2/2013

numerous and significant achievements. Those achievements came early as Nancy provided critical enzymology support to the angiotensin converting enzyme (ACE) inhibitor project for the treatment of hypertension, and multiple other targets.  Her early accomplishments also include the identification of the first caspase, interleukin-1b converting enzyme (ICE/caspase-1), and contributions to the discovery of the target of ezetimibe, the active ingredient in ZETIA™.

In 1999 Nancy became the Director of Enzymology, and then in 2001 the Director of Metabolic Disorders. It was during this same time that the full magnitude of Nancy's contributions became apparent. She initiated the DPP-4 program in 1999, and co-led the team resulting in the discovery of Januvia™ (sitagliptin) in 2001. Sitagliptin is currently the #1 branded oral agent for the treatment of type 2 diabetes, and the largest selling product in Merck history. 

In 2007 Nancy became a Vice President and Worldwide Basic Research Head for Diabetes and Obesity, and then again was promoted in 2009 to SVP and Franchise Head of Diabetes and Obesity. Finally in 2011 Nancy became SVP and Franchise Head of Diabetes and Endocrinology for Merck Research Laboratories. In this role, she was responsible for strategy and pipeline management for R&D in the areas of diabetes, osteoporosis, fertility, and contraception, and numerous programs advanced under her leadership.

In addition to a prolific publishing record, Nancy has been awarded numerous times for her accomplishments, including in 2011 the PhRMA Discoverers Award. She has guest lectured at prestigious venues, as well as chaired many key scientific and medical sessions.

Nancy explained that she was drawn to the Intarcia Board opportunity because of the Company's capabilities and culture of innovation, and her assessment that ITCA 650 has the potential to make a real difference in the lives of patients with type 2 diab
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Intarcia Therapeutics Secures Landmark $210 Million Financing To Fund Its Global Phase 3 Program For ITCA 650 In Type 2 Diabetes
2. Intarcia Announces Expanded Appointment for Kurt Graves as Chairman, President and Chief Executive Officer
3. Scientists develop way to successfully give nanoparticle therapeutics orally
4. Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Dose-Ranging Field Study in Client-Owned Dogs with Osteoarthritis
5. Northwest Biotherapeutics Announces Pricing Of Public Offering Of Common Stock And Warrants
6. Aratana Therapeutics to Present at Two Upcoming Investor Conferences
7. Jade Therapeutics Elects Veteran Life Science Entrepreneur Dinesh Patel, Ph.D., to its Board of Directors
8. Argos Therapeutics Presents Data Showing Memory T Cell Expansion After Administration of Fully Personalized Immunotherapy Correlates with Overall Survival Benefit in Patients with Metastatic Renal Cell Carcinoma
9. Global Aptamers Market Technology Trend Analysis Market Report 2013-2018: Therapeutics, Diagnostics, Biosensors, Biomarker/Drug Discovery & Applications
10. Acquisitions, Project Announcements & Trend Analysis News for Oxygen Biotherapeutics, Glu Mobile, Cisco Systems, Barrick Gold, CVS Caremark
11. Convoy Therapeutics Appoints Clinical Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Freeslate, Inc ., the leading ... Lupin Limited, one of India’s top five pharmaceutical companies, ... System for high throughput solid form screening. ... a wide range of quality, affordable generic and branded ...
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
(Date:1/14/2014)...   Kinaxis ®, provider of RapidResponse ®, a cloud-based ... planning ( S&OP ) service, is proud to be a ... be held at the Hilton San Diego Bayfront, January 30 ... Elisabeth Kaszas , Director of Supply Chain at Amgen, as ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... NEW YORK, March 9, 2011 Reportlinker.com announces ... in its catalogue: World Market ... and What,s Not, The ... predictions made about the molecular diagnostics but to ...
... 2011 SPX Corporation (NYSE: SPW ) ... B.W. Murdoch Ltd, a leading engineering company supplying processing ... is based in Auckland, New Zealand. Terms of the ... has decades of experience in the New Zealand dairy, ...
... 2011 AccessClosure, Inc., the U.S. market segment ... from the first published study* (Journal of NeuroInterventional ... different vascular closure devices (VCD) as the primary ... the discomfort associated with the Mynx 5F Vascular ...
Cached Biology Technology:Reportlinker Adds World Market for Molecular Diagnostics: Potential and Reality, What's Hot and What's Not , The 2Reportlinker Adds World Market for Molecular Diagnostics: Potential and Reality, What's Hot and What's Not , The 3SPX Announces Acquisition of B.W. Murdoch Ltd, Broadening Process Engineering and Project Management Capabilities in New Zealand and the Asia Pacific Region 2Significant Reduction in Pain With the Mynx Vascular Closure Device Versus Angio-Seal Device 2Significant Reduction in Pain With the Mynx Vascular Closure Device Versus Angio-Seal Device 3
(Date:4/17/2014)... in bone marrow need to produce hydrogen sulfide in ... to a new study from the Center for Craniofacial ... of USC. , Professor Songtao Shi, principal investigator on ... by the cells governs the flow of calcium ions. ... that results in osteogenesis, or the creation of new ...
(Date:4/17/2014)... Ongoing deforestation and fragmentation of forests in the ... remnant forests, contributing to rapid and widespread forest ... of researchers., The findings show that forests in ... severe droughts coupled with forest fires lead to ... said Jennifer Balch, assistant professor of geography, Penn ...
(Date:4/17/2014)... have detected new early-warning signs of the potential loss ... far-reaching implications for the diagnosis and treatment of diabetic ... Americans. , "We had not expected to see such ... said Ann Elsner, professor and associate dean in the ... study. "We set out to study the early signs, ...
Breaking Biology News(10 mins):Drought and fire in the Amazon lead to sharp increases in forest tree mortality 2Drought and fire in the Amazon lead to sharp increases in forest tree mortality 3New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3
... FASEB MARC (Maximizing Access to Research Careers) ... the American Association of Immunologists 2013 Introductory Course ... 13-18, 2013. These awards are meant to promote ... underrepresented groups into the mainstream of the basic ...
... households could go a long way to reducing greenhouse gas ... energy demands at the household level, appears in the ACS ... and colleagues point out that the energy people use to ... for more than 70 percent of emissions of carbon dioxide, ...
... and radical rethink, into how it produces chemicals if it ... gas emission reduction targets of 80% plus by 2050. ... report issued today by the University of Manchester,s Tyndall Centre ... to produce chemicals in 2050?, the report was generated in ...
Cached Biology News:Major rethink needed if chemical industry is to meet greenhouse gas targets 2Major rethink needed if chemical industry is to meet greenhouse gas targets 3
a1-Antitrypsin (human, alpha-1 AT)...
... vesicles are used to study co-translational ... Processing events such as signal peptide ... glycosylation can be examined by the ... vitro in the presence of these ...
... using Mo Bio luciferase assay. Mo Bio Laboratories ... will allow you to certify your products ATP-Free ... you to deliver them to your customers in ... limit is 3.5 x 10-12 /l, which will ...
... New Concept in Microarrays: Biomedical Photometrics Inc. ... GmbH (Jena, Germany) have collaborated to develop ... ArrayTube System. The DNAscope AT is ... new DNAscope AT automatically reads up to ...
Biology Products: